Tomas G Olsson (Former)
21 – 30 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
A Peristaltic Pump Driven Zr-89 Separation Module
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2011
-
Mark
Effect of charge on microvascular permeability in early experimental sepsis in the rat.
(
- Contribution to journal › Article
- 2010
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
- 2009
-
Mark
Comparison of cisplatin sensitivity and the 18F fluoro-2-deoxy 2 glucose uptake with proliferation parameters and gene expression in squamous cell carcinoma cell lines of the head and neck
(
- Contribution to journal › Article
-
Mark
Prediction of patient outcome with 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography early during radiotherapy for locally advanced cervical cancer.
(
- Contribution to journal › Article
-
Mark
Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
2009) 6th Annual Conference of the European-Neuroendocrine-Tumor-Society In Neuroendocrinology 90(1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro.
(
- Contribution to journal › Article
- 2008
-
Mark
Regional cerebral metabolic rate (positron emission tomography) during inhalation of nitrous oxide 50% in humans
(
- Contribution to journal › Article
-
Mark
Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.524-525(
- Contribution to journal › Published meeting abstract